Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.
The present study was aimed to evaluate the impact of LVSI on survival in patients with early stage endometrioid endometrial cancer.

On this week's episode of Aggrego Pulse, Dr Brian Van Tine, a professor of Sarcoma Oncology at Washington University in St.
New study findings from a clinical trial by researchers at UC San Francisco and Gladstone Institutes demonstrates that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes.
A substantial proportion of patients with heavily pretreated multiple myeloma responded to treatment with the bispecific antibody talquetamab, according to results of a phase I study published in
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->